64
Competition Bureau completes preliminary investigation of relabelled biologic drugs* The Competition Bureau has completed its preliminary investigation into potential anti-competitive harm from relabelled biologic drugs. Relabelled biologic drugs are identical to originator biologic drugs but (...)